000009260 001__ 9260 000009260 005__ 20240410111845.0 000009260 0247_ $$2DOI$$a10.6083/0p096760j 000009260 037__ $$aIR 000009260 041__ $$aeng 000009260 245__ $$aInterferon Lambda in the pathogenesis of Inflammatory Bowel Disease 000009260 260__ $$bOregon Health and Science University 000009260 269__ $$a2021 000009260 336__ $$aAbstract 000009260 520__ $$aInterferon lambda is critical for host viral defense at mucosal surfaces and contributes unique immunomodulatory effects primarily in epithelial cells. Although expressed at low levels in many cell types, the interferon lambda receptor is preferentially expressed in epithelial cells and it is well established that intestinal epithelial cells play a critical role in the pathogenesis of Inflammatory Bowel Disease. There are four different interferon lambdas in humans (IFN-λ 1 through 4) which may have non-overlapping roles in the pathogenesis of Ulcerative Colitis and Crohn's Disease. The role of interferon lambda in these diseases is complex as it appears to have a role in healing epithelial tissues, while simultaneously being correlated with worsened intestinal inflammation. It is also possible that interferon lambda promotes important tissue protective effects against excessively robust inflammation by acting on other cell types, such as neutrophils. Due to its ability to restrict viral infection without inducing collateral hyperinflammation, much recent discussion has occurred concerning the therapeutic potential of IFN-λ, especially for prevention of Acute Respiratory Distress Syndrome. This mini review discusses current thought on the role of interferon lambda in the pathogenesis of inflammatory bowel disease, current gaps in the research, and therapeutic potential of interferon lambda. 000009260 540__ $$fCC BY 000009260 542__ $$fIn copyright - joint owners 000009260 650__ $$aVirus Diseases$$027847 000009260 650__ $$aCrohn Disease$$017200 000009260 650__ $$aEpithelial Cells$$018550 000009260 650__ $$aInterferons$$020914 000009260 650__ $$aInflammatory Bowel Diseases$$028222 000009260 650__ $$aInterferon Lambda$$014084 000009260 650__ $$aColitis, Ulcerative$$016889 000009260 6531_ $$amaltoporins 000009260 6531_ $$atype iii interferons 000009260 691__ $$aSchool of Medicine$$041369 000009260 7001_ $$aWallace, Jonathan$$uOregon Health and Science University$$041354 000009260 7001_ $$aConstant, David$$uOregon Health and Science University$$041354 000009260 7001_ $$aNice, Tim$$uOregon Health and Science University$$041354 000009260 711__ $$aResearch Week$$uOregon Health and Science University$$d2021 000009260 8564_ $$9b7c2499b-11db-464e-9ca2-644fe704d335$$s102525$$uhttps://digitalcollections.ohsu.edu/record/9260/files/Wallace-Jonathan-OHSU-ResearchWeek-2021.pdf 000009260 905__ $$a/rest/prod/0p/09/67/60/0p096760j 000009260 980__ $$aResearch Week